CJC-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-17 and is reviewed periodically as new material appears.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off white powder | Typical lyophilized form |
| Water solubility | Soluble | May need a small organic co-solvent |
| Purity assessment | Chromatographic peak area | Most certificates report a percentage figure |
| Storage temperature | Minus 20 C or lower | Dry, dark, sealed container |
| Identity check | Electrospray mass spectrometry | Compared against theoretical mass |
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Among the projects that SASO set its members to conduct in the holidays were repairs to schools, house-building, and instructions on financial management and agricultural techniques. Healthcare was also a priority, with SASO members focusing on primary and preventative care.
== Interactions == Miconazole is partly absorbed in the intestinal tract when used orally, as with the oral gel, and possibly when used vaginally. This can lead to increased concentrations of drugs that are metabolized by the liver enzymes CYP3A4 and CYP2C9, because miconazole inhibits these enzymes. Such interactions occur for example with anticoagulants of the warfarin type, phenytoin, some newer atypical antipsychotics, ciclosporin, and most statins used to treat hypercholesterolemia. These interactions are not relevant for miconazole that is applied to the skin.
The Emergence of Russian Panslavism, 1856-1870 (Columbia University Press, 1956) Riasanovsky, Nicholas Valentine (2006). A History of Russia (6th ed.). US: Oxford University Press. p. 450. ISBN 978-0-19-512179-7. Retrieved 22 September 2018. Snyder, Louis L. Encyclopedia of Nationalism (1990) pp 309–315. Tobolka Z. Der Panslavismus, Zeitschrift fur Politik, 6 (1913) Vyšný, Paul. Neo-Slavism and the Czechs, 1898-1914 (Cambridge University Press, 1977). Yiǧit Gülseven, Aslı (26 October 2016). "Rethinking Russian pan-Slavism in the Ottoman Balkans: N.P. Ignatiev and the Slavic Benevolent Committee (1856–77)". Middle Eastern Studies. 53 (3): 332–348. doi:10.1080/00263206.2016.1243532. hdl:11693/37207. ISSN 0026-3206. S2CID 220378577. "Pan-Slavism" in Columbia Encyclopedia
== Interactions == Previously, doxycycline was believed to impair the effectiveness of many types of hormonal contraception due to induction of CYP450 enzymes (a family of liver enzymes that break down drugs, potentially accelerating the metabolism of hormonal contraceptives). Research has shown no significant loss of effectiveness in oral contraceptives while using most tetracycline antibiotics (including doxycycline), although many physicians still recommend the use of barrier contraception for people taking the drug to prevent unwanted pregnancy.
Sources: en.wikipedia.org
In 2010, due to a rise in foreign competition, Ajinomoto began restructuring to focus on several of its products while divesting others. The company divested its Calpis beverage unit in Japan in 2012, the Ajinomoto Sweetener Company (France) in October 2015, and Amoy Food (China) in November 2018. Ajinomoto decided to focus on its food and biomedical divisions, and acquired the contract manufacturing organization Althea Technologies (US) in 2013, the frozen food company Windsor Quality Holdings, Inc. (US) in November 2014, and the frozen food company Lavelli・Terrell・Smile (France) in November 2017. In April 2016, Ajinomoto merged its pharmaceutical division with Eisai, launching EA Pharma in Japan. In October 2017, Ajinomoto introduced a "Global Brand Logo" for use throughout the Ajinomoto group. In December 2017, Ajinomoto announced it had begun construction to expand its Kawasaki Plant, along with the construction of a new R&D building. In October 2018, Ajinomoto Althea (US) and OmniChem (Belgium) merged to form Ajinomoto Bio-Pharma Services, but in April 2025, all of Althea shares were transferred to Packaging Coordinators Inc. In April 2020, the Ajinomoto Group Nutrient Profiling System for Product, which has been developed as a method to scientifically estimate the nutritive value of products such as powdered soup and frozen foods, was introduced globally to about 500 kinds of group products in seven countries. In August, Ajinomoto announced its participation in the international environment initiative RE100 for renewable energy.
=== Disinfection === Much research has been done in evaluating the ability of the silver ion at inactivating Escherichia coli, a microorganism commonly used as an indicator for fecal contamination and as a surrogate for pathogens in drinking water treatment. Concentrations of silver nitrate evaluated in inactivation experiments range from 10–200 micrograms per liter as Ag+. Silver's antimicrobial activity saw many applications prior to the discovery of modern antibiotics, when it fell into near disuse. Its association with argyria made consumers wary and led them to turn away from it when given an alternative.
is in g/mol. However, this method can be used, only when the gas pressure is low (of the order of few mbar). At higher pressures (tens of millibars or more), pressure or collisional broadening becomes important and the lineshape is no longer a function of temperature alone.
Sources: en.wikipedia.org
anomer Either of a pair of cyclic hemiacetal or hemiketal saccharides that are epimers of each other, differing at only one carbon stereocenter, specifically the carbon that bears the aldehyde or ketone functional group in the compound's acyclic, open-chain configuration, known as the anomeric carbon.
=== Intestinal colonization and sepsis === Enterohemorrhagic E. coli (EHEC) and enteropathogenic E. coli (EPEC) are pathogens that rely on OmpT to colonize in the intestine of their host. In response to the presence of E. coli in the gut, the host releases antimicrobial peptides as part of the innate immune response. Since OmpT can break down these antimicrobials and inactivate them, EHEC and EPEC can colonize within the colon or small intestine of the host and lead to serious diarrheal diseases. In the case of sepsis, the host activates the blood clotting system to deposit fibrin and limit the spread of bacteria throughout the blood. However, OmpT can inactivate the tissue factor pathway inhibitor (TFPI), counteracting the host's immune response, and further perpetuating the spread of extraintestinal E. coli infection.
The most recently named elements – nihonium (113), moscovium (115), tennessine (117), and oganesson (118) – completed the seventh row of the periodic table. Future elements would have to begin an eighth row. These elements may be referred to either by their atomic numbers (e.g. "element 164"), or by the IUPAC systematic element names adopted in 1978, which directly relate to the atomic numbers (e.g. "unhexquadium" for element 164, derived from Latin unus "one", Greek hexa "six", Latin quadra "four", and the traditional -ium suffix for metallic elements). All attempts to synthesize such elements have failed so far. Attempts to make element 119 have been ongoing since 2018 at the Riken research institute in Japan and since 2026 at the JINR in Russia, and an attempt to make element 120 has been ongoing since 2025 at the LBNL in the United States. The Heavy Ion Research Facility in Lanzhou (HIRFL) in China also plans to make its own attempts at synthesizing the first few period 8 elements. If the eighth period followed the pattern set by the earlier periods, then it would contain fifty elements, filling the 8s, 5g, 6f, 7d, and finally 8p subshells in that order. But by this point, relativistic effects should result in significant deviations from the Madelung rule. Various different models have been suggested for the configurations of eighth-period elements, as well as how to show the results in a periodic table. All agree that the eighth period should begin like the previous ones with two 8s elements, 119 and 120.
Sources: en.wikipedia.org
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.
Yes. Degradation proceeds faster once the powder is dissolved, especially at room temperature or after multiple freeze and thaw cycles. Working solutions are often aliquoted to avoid repeated handling. Lyophilized powder held cold and dry retains its properties far longer.
Truncated sequences, oxidized residues and aggregated forms can all elute near the main peak. Reversed phase chromatography resolves many of these species, so the number of peaks is a useful indicator of synthesis quality. A single peak does not by itself prove correct sequence, which is why mass confirmation is paired with it.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.